Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma (HCC).

The updated overall survival results for the phase III RESORCE trial of regorafenib (Stivarga) were presented at the 2017 World Congress on Gastrointestinal Cancer.

This longer follow-up has confirmed that regorafenib is an effective treatment for patients with HCC who have progressed on sorafenib (Nexavar).

<<<

View more from the 2017 World Congress on GI Cancer